证券代码：301009 证券简称：可靠股份 杭州可靠护理用品股份有限公司投资者关系活动记录表 编号：2022-003 | --- | --- | --- | |-------------------------|----------------------------------|--------------------------------------------------------------------| | | | | | 投资者关系活 | □ 特定对象调研 | □ 分析师会议 | | 动类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | 其他 | （ 投资者电话会议 ） | | 参与单位名称 及人员姓名 | 详见附件 | | | 时间 | 2022年8 月27日 | | | 地点 | 浙江省杭州市临安区锦城街道花桥路 | 2 号 | | 上市公司参与 | | 董事长兼总经理金利伟、财务总监徐鸣、证券事务代表徐思敏 | | 人员姓名 | 一、公司经营管理层介绍公司 | 2022 年半年度基本情况 | | | 公司继续 ...

证券代码：301009 证券简称：可靠股份 杭州可靠护理用品股份有限公司投资者关系活动记录表 编号：2022-005 | --- | --- | --- | |-----------------------|---------------------------------------|--------------------------------------------------------------------------------------------------------------| | | | | | 投资者关系活 | | 特定对象调研 □分析师会议 | | 动类别 | | □媒体采访 □业绩说明会 | | | □新闻发布会 □路演活动 | | | | □现场参观 | | | | 其他 | （ 投资者电话会议 ） | | 参与单位名称 | 详见附件 | | | 及人员姓名 | | | | 时间 | 2022年10月27 日 | | | 地点 | 浙江省杭州市临安区锦城街道花桥路 | 2 号 | | 上市公司参与 人员姓名 | | 董事长兼总经理金利伟、财务总监徐鸣、证券事务代表徐思敏 ...

杭州可靠护理用品股份有限公司 2022 年第三季度报告 1 2022 年第三季度报告 □是 否 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 重要内容提示： 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报 告中财务信息的真实、准确、完整。 3.第三季度报告是否经过审计 证券代码：301009 证券简称：可靠股份 公告编号：2022-053 杭州可靠护理用品股份有限公司 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 杭州可靠护理用品股份有限公司 2022 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同 | 年初至报告期末 | 年初至报告期末比 | | --- | --- | --- | --- | --- | | | | 期增减 | | 上年同期增减 | | 营业收入（元） | 272,994,762.56 | 15. ...

Financial Performance - The company's operating revenue for the first half of 2022 was approximately ¥576.13 million, a decrease of 8.59% compared to ¥630.29 million in the same period last year[26]. - The net profit attributable to shareholders of the listed company was ¥554,914.39, down 99.18% from ¥67.36 million in the previous year[26]. - The net profit after deducting non-recurring gains and losses was a loss of ¥2.82 million, compared to a profit of ¥64.60 million in the same period last year, representing a decline of 104.36%[26]. - The cash flow from operating activities showed a net outflow of ¥3.44 million, a decrease of 119.03% compared to a positive cash flow of ¥18.10 million in the previous year[26]. - Basic and diluted earnings per share were both ¥0.0020, down 99.39% from ¥0.33 in the same period last year[26]. - The weighted average return on net assets was 0.04%, a decrease of 10.37% from 10.41% in the previous year[26]. - The company reported a revenue of ¥576,126,971.60 for the current period, a decrease of 8.59% compared to ¥630,287,491.94 in the previous year, primarily due to a decline in birth rates affecting baby product sales[58]. - The company's operating costs increased by 5.69% to ¥505,938,027.07, attributed to rising material costs and logistics expenses[58]. - Sales expenses rose significantly by 33.53% to ¥49,775,326.86, driven by increased brand promotion and channel expansion efforts[58]. - Management expenses increased by 36.20% to ¥15,450,451.43, mainly due to salary adjustments and increased land costs[58]. Assets and Liabilities - Total assets at the end of the reporting period were approximately ¥2.09 billion, a slight increase of 0.03% from ¥2.08 billion at the end of the previous year[26]. - The net assets attributable to shareholders of the listed company were approximately ¥1.40 billion, down 1.31% from ¥1.41 billion at the end of the previous year[26]. - The total cash and cash equivalents decreased by 111.67% to -¥87,077,437.41, mainly due to increased fixed asset investments and dividend distributions from 2021[62]. - The accounts receivable increased to ¥246,560,421.67, representing 11.82% of total assets, up 3.36% year-on-year[66]. - Total liabilities rose to CNY 599,176,346.65 from CNY 578,586,887.87, marking an increase of about 3.4%[162]. - The company's equity attributable to shareholders decreased to CNY 1,396,245,353.40 from CNY 1,414,729,191.37, a decline of approximately 1.3%[162]. Market Position and Products - The company has a leading position in the adult incontinence products market, with a market share of 9.8% in 2021, while the overall market for absorbent hygiene products decreased by 5.9%[44]. - The compound annual growth rate for adult incontinence products consumption from 2018 to 2021 reached 18%, contrasting with a decline of 3.9% for baby diapers[45]. - The company operates under a dual-driven model of "own brand + ODM," focusing on adult incontinence, baby care, and pet hygiene products[34]. - The company has developed high-end products specifically designed for Asian women and men, including invisible absorbent pads and ultra-thin breathable adult diapers[35]. - The company has established deep partnerships with well-known baby care brands, leveraging over 20 years of industry experience[34]. - The company has upgraded its "Absorbent Treasure" product line in terms of packaging and performance starting in 2022[36]. Research and Development - The company holds a total of 271 patents, including 51 invention patents, with 22 new patents acquired in 2022, indicating strong R&D capabilities[47]. - Research and development expenses increased by 6.20% to ¥25,097,988.20, reflecting a rise in R&D investment during the reporting period[62]. - The company has implemented a strategy to manage the release of restricted shares, with specific dates for unlocking shares for various stakeholders[140]. Risks and Challenges - The company faces risks from currency fluctuations, particularly as transactions with overseas clients are typically priced and settled in USD, which may impact operational performance due to exchange rate volatility[88]. - The declining birth rate in China poses a risk to the baby hygiene products market; the company plans to expand its market share in adult incontinence products to mitigate this impact[90]. - Increased competition in the disposable hygiene products industry, especially for baby products, necessitates ongoing investment in product development and brand building to maintain market share[92]. - The company has a high customer concentration risk, primarily relying on major clients like JS in the Philippines, and aims to diversify its customer base to reduce dependency[91]. Corporate Governance and Social Responsibility - The company emphasizes the importance of risk awareness regarding forward-looking statements and potential risks in its operations[4]. - The company actively engages in social responsibility initiatives, including providing care consultations and product samples for elderly individuals during a sports event[105]. - The company celebrated the fifth anniversary of "Hope Home" in Lin'an, contributing physical donations and participating in charitable activities[106]. - The company has implemented a shareholder return program to thank investors for their support since its IPO, resulting in positive interactions[106]. Future Outlook - The company plans to expand its market presence by launching new products in the second half of 2022[192]. - The management provided a revenue guidance of 1.2 billion yuan for the full year 2022, expecting a growth rate of 5%[192]. - The company is exploring potential mergers and acquisitions to strengthen its market position and diversify its product offerings[192]. - The company aims to enhance its production capacity by 15% through strategic investments in new facilities[192].

Financial Performance - The company reported a profit distribution plan, proposing a cash dividend of 0.70 RMB per 10 shares based on a total of 271,860,000 shares[5]. - The company's operating revenue for 2021 was ¥1,186,403,782.94, a decrease of 27.44% compared to ¥1,635,131,559.07 in 2020[20]. - The net profit attributable to shareholders was ¥39,745,305.90, down 81.43% from ¥214,010,338.13 in the previous year[20]. - The net cash flow from operating activities was ¥50,525,107.06, reflecting a decline of 87.24% compared to ¥395,857,840.02 in 2020[20]. - The total assets at the end of 2021 increased by 39.60% to ¥2,085,632,908.86 from ¥1,493,966,929.22 at the end of 2020[20]. - The net assets attributable to shareholders rose by 130.63% to ¥1,414,729,191.37 from ¥613,425,459.94 in 2020[20]. - The basic earnings per share decreased by 83.81% to ¥0.17 from ¥1.05 in 2020[20]. - The weighted average return on equity dropped to 3.92% from 42.28% in the previous year, a decline of 38.36%[20]. - The company achieved a total revenue of ¥1,186,403,782.94 in 2021, representing a decrease of 27.44% compared to the previous year[65]. - The revenue from the company's own brand business was ¥391,042,204.20, accounting for 32.96% of total revenue, which is a decline of 12.05% year-on-year[69]. - The ODM business generated revenue of ¥777,881,239.90, making up 65.57% of total revenue, with a year-on-year decrease of 33.81%[69]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion CNY in 2021, representing a year-over-year growth of 15%[123]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion yuan for the fiscal year, representing a 20% year-over-year growth[194]. Market Position and Competition - The company confirmed that its main business and core competitiveness have not experienced significant adverse changes, aligning with industry trends[5]. - The company faces risks from increasing market competition and significant fluctuations in raw material prices, as detailed in the management discussion section[5]. - The disposable personal hygiene products market in China reached a scale of 121.4 billion RMB in 2020, growing by 4.2% compared to 2019[30]. - The adult incontinence products market size was 11.5 billion RMB in 2020, representing a growth of 22.5% from 2019[30]. - The company ranked first in the domestic adult incontinence products market according to the Life Paper Committee's annual report for 2021[35]. - The competitive landscape in the adult incontinence products market is intensifying, necessitating continuous product and channel innovation to maintain industry leadership[119]. - High customer concentration risk exists, with major clients being key strategic partners; the company aims to expand its customer base globally to mitigate this risk[120]. Product Development and Innovation - The company has established a strong brand image and is recognized as one of the top ten enterprises in the adult incontinence products industry in China[34]. - The company has a diverse product line including adult diapers, adult pull-ups, and nursing pads, catering to various market segments[36]. - The company is committed to product innovation and has a dedicated R&D team to enhance its product offerings[34]. - The company launched new products targeting the light incontinence market, including specially designed products for Asian women, expanding its product range[61]. - The company is developing several new products, including ultra-thin comfortable baby diapers and medical-grade baby diapers, aiming to enhance product competitiveness and market presence[83]. - New product development efforts are focused on eco-friendly nursing products, with an investment of 50 million CNY allocated for R&D in 2022[123]. - The company is investing 100 million CNY in R&D for new technologies aimed at enhancing product efficiency and user experience[193]. - The company plans to increase R&D investment in 2022, aiming to enrich its product line and meet consumer demands through innovation and collaboration with academic institutions[112]. Strategic Initiatives and Partnerships - The company operates under a dual-driven model of "own brand + ODM," focusing on both self-owned brands and high-end manufacturing[36]. - The company has formed strategic partnerships with top research institutions to enhance R&D capabilities and accelerate product development[48]. - The company has established a direct sales model with key accounts, including major retailers like RT-Mart and Walmart, enhancing market reach[44]. - The online sales strategy includes e-commerce platforms such as Tmall, JD.com, and Pinduoduo, along with emerging channels like live streaming and community group buying[45]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 300 million CNY allocated for potential mergers and acquisitions[194]. Financial Management and Governance - The company’s financial report has been confirmed as true, accurate, and complete by its management team[4]. - The company has established an independent financial accounting department with a compliant accounting system and financial management practices[136]. - The company has a complete and independent business system, capable of operating independently in the market without reliance on shareholders or related parties[139]. - The company has a clear separation of production and office locations from controlling shareholders, ensuring operational independence[138]. - The company has established a robust internal control system, ensuring compliance and effective implementation to protect shareholder rights[177]. - The company has maintained compliance with regulations set by the China Securities Regulatory Commission and the Shenzhen Stock Exchange[163]. - The company has a structured remuneration system for core technical personnel based on labor contracts and company policies[154]. - The company has committed to enhancing fundraising management to ensure proper and legal use of raised funds[198]. Risk Management - The company emphasizes the importance of risk awareness regarding forward-looking statements related to future plans and development strategies[5]. - The company faces foreign exchange risk due to pricing in USD, which may impact operating performance amid significant fluctuations in the RMB/USD exchange rate[116]. - Raw material price volatility poses a risk, but the company maintains strong bargaining power with suppliers to stabilize procurement costs[117]. - The company is exposed to macroeconomic risks, with consumer demand linked to disposable income and inflation, prompting a strategy to diversify product offerings[118]. Social Responsibility and Sustainability - The company actively engages in social responsibility initiatives, focusing on employee rights and community involvement[183]. - The company is committed to environmental protection by developing biodegradable materials for its products, contributing to pollution reduction[187]. - The company has engaged in poverty alleviation and rural revitalization efforts, including donations for local infrastructure projects[188]. - The company has a commitment to sustainability, with plans to reduce production waste by 25% over the next two years[193]. Future Outlook - The company provided a positive outlook for 2022, projecting a revenue growth of 10% to 15% based on market expansion strategies and new product launches[123]. - The company aims to expand its market presence in Southeast Asia, targeting a 25% increase in market share within the region over the next two years[123]. - The company plans to enhance its online sales channels, aiming for a 30% increase in e-commerce revenue by the end of 2022[193]. - The company aims to maintain independence in its operations and avoid any actions that could affect its independence from related parties[195].

Financial Performance - The company's revenue for Q1 2022 was ¥321,634,613.20, a decrease of 3.34% compared to ¥332,749,095.49 in the same period last year[4] - Net profit attributable to shareholders was ¥1,957,458.10, down 95.14% from ¥40,247,530.57 year-on-year[4] - Basic and diluted earnings per share fell by 96.35% to ¥0.0072 from ¥0.1974 in the same period last year[4] - Total operating revenue for the first quarter was CNY 321,634,613.20, a decrease of 3.36% from CNY 332,749,095.49 in the previous period[23] - Net profit for the first quarter was CNY 1,249,515.90, compared to CNY 42,112,413.87 in the previous period, indicating a significant decline[24] - Total comprehensive income for the period was CNY 1,250,216.49, a significant decrease from CNY 42,111,305.65 in the previous period[25] Cash Flow and Liquidity - The net cash flow from operating activities improved by 44.22%, reaching -¥26,511,328.02 compared to -¥47,527,361.16 in the previous year[4] - Cash flow from operating activities showed a net outflow of CNY 26,511,328.02, improving from a net outflow of CNY 47,527,361.16 in the previous period[28] - Cash inflow from operating activities totaled CNY 317,501,584.83, compared to CNY 404,532,070.78 in the previous period, indicating a decrease of approximately 21.5%[27] - Cash outflow from operating activities was CNY 344,012,912.85, down from CNY 452,059,431.94 in the previous period[28] - The company’s cash and cash equivalents decreased to CNY 793,596,679.93 from CNY 884,043,596.62 at the beginning of the year, a drop of 10.24%[20] - Cash and cash equivalents at the end of the period were CNY 749,542,990.39, a decrease from CNY 126,020,364.47 at the end of the previous period[29] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,079,145,718.49, a slight decrease of 0.31% from the previous year-end[5] - Total assets amounted to CNY 2,079,145,718.49, slightly down from CNY 2,085,632,908.86 at the beginning of the year[22] - Total liabilities decreased to CNY 570,849,481.01 from CNY 578,586,887.87, a reduction of 1.27%[21] Accounts and Inventory - Accounts receivable increased by 42.29%, primarily due to seasonal fluctuations in revenue and increased customer accounts[9] - Accounts receivable increased to CNY 250,953,563.50 from CNY 176,373,803.84, reflecting a rise of 42.14%[20] - Inventory decreased to CNY 118,420,173.23 from CNY 153,946,515.54, a decline of 23.05%[20] Shareholder Information - The company reported a total of 7,200,000 shares held by Hangzhou Weianuo Investment Partnership, accounting for 2.65% of the total shares[12] - Gracious Star (HK) Limited holds 6,473,507 shares, representing 2.38% of the total shares[12] - Cherish Star (HK) Limited owns 4,302,456 shares, which is 1.58% of the total shares[12] - The company has a significant shareholder, Jin Liwei, holding 161,099,964 shares, which are restricted until June 17, 2024[15] - The total number of restricted shares at the beginning of the period was 207,171,400, with no new restrictions added during the period[15] - The report indicates that there are no changes in the number of restricted shares during the current period[15] - The company has a total of 3,662,800 shares held by Guotai Junan Securities Asset Management, which is 1.35% of the total shares[12] - The total number of shares held by the top 10 unrestricted shareholders is significant, indicating a concentrated ownership structure[12] - The company has not disclosed any related party transactions among the top shareholders[13] Costs and Expenses - Total operating costs increased to CNY 318,364,386.45, up 12.00% from CNY 284,409,824.47 in the previous period[23] - The company reported a significant increase in research and development expenses to CNY 11,363,742.18 from CNY 10,681,434.75, an increase of 6.38%[23] - The company experienced a 96.31% decline in net profit after deducting non-recurring gains and losses, primarily due to rising raw material and transportation costs[8] Tax and Refunds - The company received CNY 16,995,427.58 in tax refunds, an increase from CNY 13,812,645.55 in the previous period[27] Other Matters - There are no other important matters reported in the quarterly financial report[17]

Financial Performance - The company's revenue for Q3 2021 was ¥236,315,695.47, a decrease of 45.54% compared to the same period last year[3] - The net profit attributable to shareholders was ¥2,086,358.75, down 94.32% year-on-year[3] - The company reported a basic earnings per share of ¥0.0077, a decrease of 95.72% year-on-year[3] - Total operating revenue for Q3 2021 was CNY 866,603,187.41, a decrease of 29.7% compared to CNY 1,233,194,920.14 in the same period last year[23] - Net profit for Q3 2021 was CNY 72,681,807.54, a decline of 58.3% compared to CNY 174,008,599.62 in Q3 2020[25] - The total comprehensive income for Q3 2021 was CNY 72,682,749.57, compared to CNY 174,012,199.71 in the previous period[26] - The net profit attributable to the parent company was CNY 69,449,775.33, down from CNY 168,055,416.95 year-on-year[26] - Basic and diluted earnings per share for the current period were CNY 0.2555, compared to CNY 0.8242 in the previous period[26] Cash Flow - The net cash flow from operating activities was negative at -¥11,005,787.31, representing a decline of 104.59% compared to the previous year[3] - Cash flow from operating activities decreased by 104.59% year-on-year, mainly due to a decline in revenue[12] - The company's cash flow from operating activities showed improvement, with a net cash inflow of CNY 81,485,609.99 compared to CNY 198,340,509.44 in the previous year[24] - Cash inflow from operating activities totaled CNY 1,178,410,016.99, a decrease from CNY 1,369,001,550.73 in the previous period[27] - The net cash flow from operating activities was negative CNY 11,005,787.31, compared to a positive CNY 239,777,362.56 in the previous period[29] - Cash inflow from financing activities was CNY 868,509,922.66, compared to CNY 138,900,000.00 in the previous period[30] - The net cash flow from financing activities was CNY 685,396,074.37, a substantial increase from CNY 35,294,913.31 in the previous period[30] Assets and Liabilities - Total assets increased by 35.04% to ¥2,017,416,377.49 compared to the end of the previous year[4] - The company's total assets increased to CNY 2,017,416,377.49, up from CNY 1,493,966,929.22 year-over-year, representing a growth of 35.0%[21] - Total liabilities decreased to CNY 476,638,525.32 from CNY 812,417,102.08, a reduction of 41.3%[21] - The equity attributable to shareholders rose by 135.55% to ¥1,444,920,510.73 compared to the end of the previous year[4] - The equity attributable to the parent company increased to CNY 1,444,920,510.73, compared to CNY 613,425,459.94 in the previous year, reflecting a growth of 135.5%[21] Expenses - Sales expenses increased by 40.37% compared to the same period last year, primarily due to higher marketing costs[11] - Management expenses rose by 34.37% year-on-year, mainly due to increased expenses related to the company's listing[11] - Research and development expenses for Q3 2021 were CNY 35,968,748.44, down 23.7% from CNY 47,086,194.32 in the same quarter last year[24] - Financial expenses decreased by 144.9% year-on-year, attributed to increased foreign exchange gains and interest income[11] Investments - Investment income surged by 911.53% compared to the previous year, driven by increased financial management of idle funds[11] - Cash flow from investing activities increased by 137.96% year-on-year, due to higher cash payments for investments[12] - Cash outflow from investing activities was CNY 483,027,061.64, significantly higher than CNY 193,847,859.19 in the previous period[30] - The net cash flow from investing activities was negative CNY 361,111,800.16, compared to negative CNY 151,750,125.56 in the previous period[30] Shareholder Information - The top shareholder, Jin Liwei, holds 59.26% of the shares, indicating significant control over the company[14] - The company established a new subsidiary, increasing minority interests by 40.71%[10] Future Outlook - The company plans to focus on market expansion and new product development to drive future growth[24] Cash and Equivalents - Cash and cash equivalents increased by 80.70% compared to the beginning of the year, primarily due to funds raised from the initial public offering[9] - The company's cash and cash equivalents increased to approximately ¥613 million as of September 30, 2021, compared to ¥339 million at the end of 2020[18] - The ending cash and cash equivalents balance was CNY 528,934,637.23, up from CNY 230,561,802.44 in the previous period[30]

Financial Performance - The company reported a revenue of RMB 500 million for the first half of 2021, representing a year-on-year increase of 15% compared to RMB 435 million in the same period of 2020[16]. - The net profit attributable to shareholders for the first half of 2021 was RMB 80 million, up 20% from RMB 66.67 million in the first half of 2020[16]. - Future guidance estimates a revenue growth of 20% for the full year 2021, projecting total revenue to reach RMB 1.2 billion[16]. - The company's operating revenue for the reporting period was ¥630,287,491.94, a decrease of 21.14% compared to the same period last year[22]. - The net profit attributable to shareholders was ¥67,362,474.55, down 48.71% year-over-year[22]. - The net cash flow from operating activities was ¥18,099,870.28, reflecting a significant decline of 89.81% compared to the previous year[22]. - The company reported a decrease in accounts payable to RMB 241,477,124.50 from RMB 256,887,154.13, which is a reduction of approximately 6.0%[145]. - The net profit for the first half of 2021 was ¥54,387,426.50, down 49.5% from ¥107,683,498.23 in the same period last year[158]. - The company's operating cash flow for the first half of 2021 was ¥18,099,870.28, a significant decline of 89.8% compared to ¥177,543,317.82 in the first half of 2020[161]. Market Expansion and Strategy - The company plans to expand its market presence in Southeast Asia, targeting a 25% increase in market share by the end of 2022[16]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market reach, with a budget of RMB 100 million allocated for this purpose[16]. - The company aims to increase its market share through strategic partnerships and potential acquisitions in the healthcare sector[171]. - The company plans to invest heavily in product research and development, channel expansion, and brand building to mitigate risks associated with market competition[78]. - The company has established strategic partnerships with major pharmaceutical distribution companies to enhance brand coverage and influence[51]. Research and Development - The company has invested RMB 50 million in R&D for new product development, focusing on eco-friendly materials and innovative designs[16]. - Research and development investment was ¥23,633,763.81, down 16.41% from ¥28,274,056.90, reflecting a reduction in R&D spending[55]. - The company has allocated resources for research and development to innovate new products and technologies[171]. - The company holds 247 patents, including 41 invention patents, showcasing its strong R&D capabilities[47]. Financial Position - Total assets increased by 45.61% to ¥2,175,431,195.08 compared to the end of the previous year[22]. - The net assets attributable to shareholders rose by 135.13% to ¥1,442,344,319.90 compared to the end of the previous year[22]. - The company's total assets included cash of ¥1,060,638,789.04, representing 48.76% of total assets, significantly increased due to IPO proceeds[60]. - The company's equity attributable to shareholders increased to RMB 1,442,344,319.90 from RMB 613,425,459.94, marking a substantial rise of around 134.0%[146]. - The total assets at the end of the reporting period amounted to CNY 1,401,420,000, indicating a robust financial position[177]. Operational Efficiency - The gross margin for the first half of 2021 was reported at 35%, slightly down from 37% in the same period last year due to increased raw material costs[16]. - The operating cost decreased by 11.25% to ¥478,708,424.20 from ¥539,417,494.45, also attributed to the decline in sales of epidemic prevention materials[54]. - The company has implemented new strategies to enhance operational efficiency and reduce costs[171]. Shareholder Information - The company will not distribute cash dividends for the current fiscal year, opting to reinvest profits into business expansion[6]. - The company has not distributed cash dividends or bonus shares for the half-year period and has no plans for capital reserve conversion into share capital[88]. - The total number of shares outstanding is 271,860,000, with 64,806,264 shares being unrestricted[122]. - The largest shareholder, Jin Liwei, holds 161,099,964 shares, representing 59.26% of the total shares[127]. Legal and Compliance - The half-year financial report has not been audited, and there are no significant litigation or arbitration matters reported[99][101]. - The company reported a litigation amount of 13,178.4 thousand yuan related to a contract dispute, which will not impact daily operations[102]. - The company has not reported any penalties or rectifications during the reporting period[103]. - There are no significant related party transactions reported during the period[106]. Environmental and Social Responsibility - The company is not classified as a key pollutant discharge unit and has not faced any administrative penalties for environmental issues during the reporting period[92]. - The company actively participates in social responsibility projects, particularly for the disabled, and has contributed to various charitable activities[93].